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Abstract
Background: Sodium antimony gluconate (SAG) unresponsiveness of Leishmania donovani (Ld) had effectively
compromised the chemotherapeutic potential of SAG. 60s ribosomal L23a (60sRL23a), identified as one of the over-
expressed protein in different resistant strains of L.donovani as observed with differential proteomics studies indicates
towards its possible involvement in SAG resistance in L.donovani. In the present study 60sRL23a has been characterized for
its probable association with SAG resistance mechanism.
Methodology and principal findings: The expression profile of 60s ribosomal L23a (60sRL23a) was checked in different SAG
resistant as well as sensitive strains of L.donovani clinical isolates by real-time PCR and western blotting and was found to be
up-regulated in resistant strains. Ld60sRL23a was cloned, expressed in E.coli system and purified for raising antibody in swiss
mice and was observed to have cytosolic localization in L.donovani. 60sRL23a was further over-expressed in sensitive strain
of L.donovani to check its sensitivity profile against SAG (Sb V and III) and was found to be altered towards the resistant
mode.
Conclusion/Significance: This study reports for the first time that the over expression of 60sRL23a in SAG sensitive parasite
decreases the sensitivity of the parasite towards SAG, miltefosine and paramomycin. Growth curve of the tranfectants
further indicated the proliferative potential of 60sRL23a assisting the parasite survival and reaffirming the extra ribosomal
role of 60sRL23a. The study thus indicates towards the role of the protein in lowering and redistributing the drug pressure
by increased proliferation of parasites and warrants further longitudinal study to understand the underlying mechanism.
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Introduction
Leishmaniasis is a neglected tropical disease, affecting almost,
more than 10 million people around the world and ranks itself
second to malaria in terms of mortality and morbidity. It is caused
by an obligatory intracellular protozoan parasite of the genus
Leishmania and has varied clinical spectrum from self healing skin
ulcers to fatal visceral infection if left untreated. As vaccine against
visceral form is still a distant proposition, treatment against
Visceral Leishmaniasis (VL) solely relies on chemotherapy.
Unfortunately, during the last decade Sodium Antimony Gluco-
nate (SAG) which had a traditional background of sixty years of
chemotherapy has been worn out due to the resistance developed
against this drug. This has become a major obstacle to the
treatment, especially in India, where more than 60% of VL
patients are unresponsive to SAG treatment. Although, new drugs
have become available in recent years for treatment of VL, they
are also far from satisfactory [1]. This is due to increased relapse
cases, lack of cost effectiveness and emerging resistance against
them, as reported earlier [2]. Therefore, understanding the
resistance mechanism could only strengthen the search for safe
and wise chemotherapeutic strategies against VL.
SAG having Sb (V) is a pro-drug and requires biological
reduction to active form i.e. Sb (III) in macrophage and/or
amastigotes. Sb (III) has been reported to interact with several
targets. Resistance in general has been understood as interplay
among uptake, efflux and/or sequestration of active molecule and
modulating gene expression levels [3]. Most of the drug resistance
studies were done on the laboratory mutants as compared to the
clinical isolates. Although some studies emphasized on field isolates
but these were based on biochemical, biophysical and immuno-
logical analysis of resistant isolates but several questions remains
unrequited regarding the parasite’s modulation for SAG at
molecular level [4,5]. Actual scenario could be more lucid by
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exploring clinical isolates and characterizing the up regulated as
well as down regulated proteins in the resistant strains. Several
differential studies revealed many proteins under several metabolic
pathways, proteins involved in maintaining redox balance,
transporters and signaling pathways along with a large number
of translational/ribosomal proteins indicating its possible role in
resistance mechanism in the resistant clinical isolates [6,7,8]. Some
of them are well characterized for their possible role in SAG
resistance mechanism e.g. Trypanothione reductase, c glutamyl
cysteine synthtase, ornithine decarboxylase and ABC transporters
but ribosomal proteins are yet to be explored for its involvement in
drug resistance against VL [9]. 60s ribosomal L23a (60sRL23a) is
one such over-expressed protein in SAG resistant strain of
Leishmania donovani (Ld) identified through differential proteomics
indicating its possible involvement in SAG resistance in L.donovani
[10].
60sRL23a encoded protein is a component of 60s subunit of
large subunit of ribosome. In eukaryotes, ribosome biogenesis is a
coordinated assembly involving four ribosomal rRNA molecules
and more than seventy ribosomal proteins. It was believed that
ribosome were previously consists of RNA only and ribosomal
protein appeared later in the evolution to facilitate the protein
synthesis. However, ribosomal proteins have also been reported to
regulate cell growth and apoptosis apart from their regular
translational apparatus activity [11]. There are some circumstan-
tial evidences available regarding ribosomal proteins acting as
modulators and effectors of changes [12]. Ribosomal proteins may
be meant for ribosome, but could be recruited for extra ribosomal
functions [13]. In the present study for the first time involvement
of over-expressed 60sRL23a in in vitro SAG resistance has been
explored in clinical isolates of L.donovani.
Materials and Methods
Parasites
Clinical isolates used in this study were isolated from patients at
the Kala –Azar Medical Research centre, Institute of Medical
Sciences, Banaras Hindu University, Varanasi, India, and at its
affiliated hospital at Muzaffarpur, Bihar, India. Clinical isolates
were obtained prior to drug treatment from VL patients who had
responded to chemotherapy by SAG and were designated as SAG-
S (SAG-sensitive), whereas VL patients who did not respond to
SAG were designated as SAG-R (SAG-resistant). Promastigotes of
corresponding strains were harvested by transformation of
amastigotes from the splenic aspirates of kala-azar patients.
SAG-S isolates used in this study include 2001 (S1) whereas the
three SAG-R isolates were 2039 (R1), 1216 (R2), 761 (R3). The
isolates used in this study were anonymized. The Dd8 (S2) strain
(MHOM/IN/80/DD8) was used as a reference strain in this
study. The isolates were maintained in RPMI-1640 medium
containing 10%FCS at 26uC (Sigma, USA) in 75 cm2 culture flask
(Nunc). The virulence have been retained in parasites through
regular passage through hamster, so as to maintain their
chemosensitivity profiles that was measured periodically by
amastigote macrophage J774A.1 infectivity assay as described
elsewhere [14].
SAG sensitivity of clinical isolates in vitro and in vivo
In vitro assay. Mouse macrophage cell line, J774A.1, was
cultured in Dulbecco’s modified Eagle’s medium (DMEM)(Sigma,
USA) in 16 well chamber slides (Nunc, USA) to a cell density of
105 cells/well and infected with late log phase promastigotes (S1,
S2, R1, R2, R3) at a multiplicity of infection of 10:1 (parasite/
macrophage) and incubated at 37uC in 5% CO2 for 8–12 h after
which chamber slides were washed with PBS and finally the wells
were supplemented with fresh medium. Different concentrations
of SAG [Sb (V) (Albert David)] were added to the wells in
triplicate and incubated for 48–96 h. Chamber slides were fixed in
absolute methanol, stained with Geimsa and examined under oil
immersion objective of light microscope. At least 100 macrophages
were counted per well for calculating % infected macrophages.
Percentage inhibition (PI) of parasite multiplication was calculated
in comparison to untreated/control using the formula: PI = no. of
parasite count from infected control – no. of parasites from the
treated group/no of parasite count from infected control per 100
macrophages [15]. Sb (III) (Sigma) sensitivity of parasite isolates
(Promastigotes) was analyzed as described elsewhere [16].
In vivo assay. Golden hamsters were infected intracadially
with 16107 late log phase promastigote of clinical isolates (S1, S2,
R1, R2, R3), per 0.1 ml of 16PBS. Parasitic burden were assessed
on day 20–25 post infection by performing splenic biopsies as
described previously [17]. Once the infection sets in with
promastigote form, further passages in hamsters were carried out
with splenic amastigotes as described previously [18]. Animals
carrying 20–30 days old infection were employed for SAG
sensitivity assay. Infected hamsters (5 animals for each dose of
different clinical isolates) were treated intraperitoneally (i.p.) with
SAG at doses of 80, 40 and 20 mg/kg body weight. Five infected
hamsters were kept as untreated control. Splenic biopsies were
again performed on day 7 post treatment after administration of
last dose of SAG. Parasitic burden of both treated and untreated
were infected animals was assessed with smear touch blots of
spleen of hamsters and percentage parasite inhibition in treated
animals was calculated by as per formula described elsewhere [15].
Cloning expression and purification of recombinant
Ld60sRL23a
L.donovani genomic DNA was isolated from 108 cultured
promastigotes [19]. Genomic DNA was spooled and subjected to
RNase (100 mg/ml) treatment. 60sRL23a gene was amplified
using primers: forward 59GGTACCATGCCTCCTGCTCA-
GAAG39 and reverse59 AAGCTTGACAAGACCGATCTT39
Author Summary
Visceral Leishmaniasis (VL) is the most fatal form in Indian
subcontinent. Till last few years, the treatment of the
disease was done with Sodium antimony gluconate (SAG),
the first line drug against VL. This, however, was severely
eroded by the resistance developed by the parasite
against it. In order to understand the underlying mecha-
nism, earlier a proteomic analysis of SAG sensitive as well
as SAG resistant isolates of L.donovani (Ld) was done in
which 60s ribosomal L23a (Ld60sRL23a) protein, one of the
essential member of translational machinery, was found to
be over-expressed. To examine its role in SAG resistance
mechanism, which is hitherto not known, 60sRL23a was
characterized and over-expressed in the sensitive isolate of
L.donovani. The sensitivity of these transfectants, was
found to be decreased towards SAG. The growth curve of
transfectants clearly showed its proliferation potential in
both promastigote and amastigote forms. Cell cycle
analysis of the transfectants further assured its rapid
progression towards the G2/M phase. The above studies,
thus, indicate that 60s RL23a regulates proliferation of
L.donovani parasites and represents a unique strategy to
resist SAG. 60sRL23a could be further explored as a
potential drug target to strengthen the chemotherapy
strategy against L.donovani.
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and Taq DNA polymerase (Sigma Aldrich) lacking 39-59
exonuclease activity in a termocycler (Bio-Rad) under conditions
at one cycle of 95uC for 5 min, 30 cycles of 95uC for 45 s, 54uC for
30 s, 72uC for 45 s, and finally one cycle of 72uC for 10 min.
Amplified PCR product was electrophoresed in agarose gel and
eluted from the gel by Gen Elute columns (Qiagen). Eluted
product was cloned in pTZ57R/T (T/A) cloning vector
(Fermentas) and transformed into competent DH5a cells. The
transformants were screened for the presence of recombinant
plasmids with 60sRL23a insert by gene specific PCR under similar
conditions as previously mentioned. Isolated positive clones were
sequenced from Chromous Biotech Pvt Ltd. (Bangalore) and
submitted to the National Centre for Biotechnology Information
http://www.ncbi.nlm.nih.gov/nuccore/GU121098.1 (accession
no. GU121098.1). 60sRL23a was further sub cloned at the KpnI
and HindIII site of bacterial pTriEx4 (Novagen). The expression of
60sRL23a was checked in bacterial cell by transforming the
60sRL23a+pTriEx4 in Escherichia coli Rosetta Strain. The
transformed cells were inoculated into 5 ml test tube culture
medium (Luria Bertani) and allowed to grow at 37uC in a shaker at
220 rpm. Cultures in logarithmic phase (at OD600 of ,0.5–0.6)
were induced for 3 hrs with 1 mM isopropyl-ß-D-thiogalactopyr-
anoside (IPTG) at 37uC. After induction cells were lysed in SDS-
Sample buffer using 56 stock (0.313 M Tris-Hcl(pH 6.8), 50%
glycerol, 10%SDS) [20]. Uninduced control culture was analyzed
in parallel. These separated proteins from the polyacrylamide gel
were transformed onto a nitrocellulose membrane in a semidry
blot apparatus (Amersham) as described elsewhere [21]. Mem-
brane was incubated for 1 h in blocking buffer followed by a 2 h
incubation at room temperature with mouse anti-His antibody
(Novagen) as primary antibody (1:2500 dilution) and then
incubated with goat anti-mouse HRP conjugate antibody (1/
10,000: Bangalore Genie) for 1 h at room temperature. The blot
was developed using an ECL kit (GE Biosciences). For purification
of 60sRL23a 200 ml of LB medium containing 35 mg/mL of
chloramphenicol and 35 mg/mL ampicillin were inoculated with
E.coli Rosetta strain transformed with pTriEx4-Ld60sRL23a and
grown to an O.D.600 of, 0.6 and then induced by addition of
1 mM (IPTG, Sigma) then further incubated for an additional 4–
5 h at 37uC. The rLd60sRL23a was purified by affinity
chromatography using Ni2+ chelating resin to bind the His6-
Tag fusion peptide derived from the pTriEx4 vector. The cell
pellet was resuspended in 5 mL of lysis buffer (10 mM Tris-HCl
(pH 8.0), 200 mM NaCl,) containing 1:200 dilution of protease
cocktail inhibitor (Sigma) and incubated for 30 mins on ice and
the suspension was sonicated for 10620 s (with 30 s interval
between each pulse) on ice. The sonicated cells were centrifuged at
15,000 g for 30 min, and the supernatant was incubated at 4uC
for 1 h with the 2 ml of Ni-NTA Superflow resin (Qiagen, Hilden,
Germany) previously equilibrated with lysis buffer. After washing
with buffer (10 mM Tris-HCl, 200 mM Nacl) containing different
concentrations of imidazole i.e. 10, 20, 30 and 50 mM, the
purified rLd60sRL23a was eluted with elution buffer (10 mM
Tris-HCl, 200 mM NaCl, and 200 mM imidazole, pH 7.5). The
eluted fractions were analysed by 12% SDS-PAGE and the gels
were stained with Coomassie brilliant blue R-250 (Sigma-Aldrich,
St.Louis, USA). The protein content of the fractions was estimated
by the Bradford method using bovine serum albumin (BSA) as
standard.
Production of polyclonal antibodies against rLd60sRL23a
and western blot analysis
The purified rLd60sRL23a was used for raising antibodies (Ab)
in swiss mice. Swiss mice were first immunized using 25 mg of
rLd60sRL23a in Freund’s complete adjuvant. Twelve days after
the first dose the mice were given 2 booster doses of 15 mg of the
recombinant protein each in incomplete Freund’s adjuvant at 15
days interval and blood was collected after the last immunization
by sacrificing the mice for serum collection. For immunoblotting
experiment, purified rLd60sRL23a protein and whole cell lysate
(WCL) were resolved on 12% SDS-PAGE and transformed onto
nitrocellulose membrane using a semi-dry blot apparatus (Amer-
sham) [21]. After overnight blocking in 5% BSA, the membrane
was incubated with antiserum to the rLd60sRL23a protein at a
dilution of 1:3000 for 120 min at room temperature (RT). The
membrane was washed three times with PBS containing 0.5%
Tween 20 (PBS-T) and then incubated with Rat anti-Mouse IgG
HRP conjugate (Invitrogen, Carlsbad, USA) at a dilution of
1:10,000 for 1 h at room temperature. Blot was developed by
using diaminobenzidine+imidazole+H2O2 (Sigma).
Immunolocalization studies. The expression of 60sRL23a
at the appropriate cellular localizations was confirmed by
immunofluorescence using polyclonal Ab raised in swiss mice
against r60sRL23a. Ld (S1) parasites were plated on four 18 mm
cover slips (BLUE STAR) and fixed using 4% paraformaldehyde.
Two of them were permeabilized by 0.5% Triton X-100 for 7 min
followed washing with 16PBS. One permeabilized and one non-
permeabilized coverslips (positive controls) were incubated with
the same primary antibody followed by washing with 16PBS and
then incubated with secondary anti-mouse FITC conjugate
(Banglore Genei) for 1 h at room temperature. After washing in
PBS, cover slips were mounted upside down on glass slides with
Fluorescent Mounting Media (CALBIOCHEM) and visualized
directly under fluorescence microscope (Eclipse 80i Nikon) using
1006 oil objective (1.4 NA). Cells transfected with
60srL23a+pXG-’GFP+, were visualized directly under the same
fluorescent microscope [15].
Homology modeling. Amino acid sequence of L. donovani
60sRL23a (Uniprot id: D1M863) was used for homology modeling.
The Hidden Markov model based profile-profile alignment
algorithm available at HHpred server on the bioinformatics toolkit
platform of the Max Planck Institute for Developmental Biology
(http://toolkit.tuebingen.mpg.de/hhpred) was used to find best
template in PDB database for homology modeling with default
settings [22]. HHpred uses HMM based profile-profile alignment
method for identification and alignment of homologous protein.
After ensuring high degree of accuracy in alignment, ten homology
models were built using Modeller 9.10 with thorough optimization
[23]. Final model was selected on the basis of DOPE score and
structural validations were performed by using SAVS server.
(http://nihserver.mbi.ucla.edu/SAVES_3/).
Real time quantitative analysis of 60sRL23a expression in
clinical isolates
10 million log phase parasites each of S1, S2, R1, R2, R3 were
taken for RNA extraction. The freshly harvested promastigotes
were immediately resuspended in Tri reagent (Sigma, Aldrich).
RNA was isolated according to the manufacture protocol. Isolated
RNA were treated with DNase and quantified in Gene-quant
(Biorad). Total RNA (1 mg/reaction) was reverse transcribed using
first-strand cDNA synthesis kit (Fermentas) and then cDNA was
treated with RNase. For qRT-PCR primers were designed using
Beacon Designer software (Biorad). qRT-PCR was carried out
with 12.5 ml of SYBER green PCR master mix (TAKARA), 1 mg
of cDNA, and primers at a final concentration of 200 nM in a final
volume of 25 ml. PCR was conducted under the following
conditions: initial denaturation at 95uC for 10 min followed by
40 cycles, each consisting of denaturation at 95uC for 1 min,
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annealing at 52uC for 1 min and extension at 70uC for 1 min
followed by 80uC for 10 sec. 87 cycles of melt curve was set at
52uC for 10 sec. All quantification was normalized to the Ld-actin
gene. A no-template control cDNA was included to eliminate
contaminations or nonspecific reactions. The cycle threshold (CT)
value was defined as the number of PCR cycles required for the
fluorescence signal to exceed the detection threshold value
(background noise). Difference in gene expression was calculated
by comparative CT method [24]. This method compares test
samples to the comparator sample and uses results obtained with a
uniformly expressed control gene (Ld-actin) to correct for
differences in the amounts of RNA present in the two samples
being compared to generate a DCT value. Results are expressed as
the degrees of difference between DCT values of test and
comparator sample (S1) to get DDCT i.e. [25]. Then the
normalized expression ratio was calculated as 22DDCT [26].
Overexpression of Ld60sRL23a in sensitive strain of Ld
60sRL23a gene was amplified from 60sRL23a+pTriEx4 con-
struct using primers: forward 59 GGATCCATGCCTCCTGCT-
CAGAAGACC39 and reverse 59 GATATCGACAAGACG-
GATCTTGTTGGCAG39 and then cloned into Leishmania
expression vector pXG-’GFP+ at BamHI and EcoRV site [27].
Late log phase S1 promastigotes were washed with transfection
buffer (21 mM HEPES,pH 7.5, 137 mM NaCl, 5 mM KCl,
0.7 mM Na2HPO4, 6 mM glucose). Transfection of the parasites
with 20 mg of 60sRL23a+pXG-’GFP+ and pXG-’GFP+ alone,
were carried out in 0.2 cm electroporation cuvet using a Gene
Pulsar (Bio-Rad). Transfectants were allowed to recover for 24 h
and then were selected for resistance to G418 at 5, 10, 20, 50 mg/
mL.
Growth profile of transfectants S1 (60sRL23a+pXG-’GFP+)
and S1(pXG-’GFP+) -
26106 parasites (promastigote) were seeded. Counting of
parasites (promastigote) for each transfectants was done for 8
days. Growth curve was plotted as number of parasites versus
number of days. The proliferative potential of transfectants at
amastigote stage was studied in macrophage amastigote (1:8)
system in chamber slide. Parasites in macrophages were counted
by geimsa staining at 0 h, 6 h, 12 h, 24 h, 48 h.
Cell cycle analysis. Log phase promastigotes were synchro-
nized with 0.3 mM hydroxyurea for 16 hrs. Then the parasites
were washed to remove hydroxyurea. Cells were fixed at 0, 3, 6,
12 h in 70% ethanol for 2 h on ice and then resuspended in
0.5 mL PBS containing 0.5 mg PI and 50 mg RNase A and
incubated for 1 h in dark at room temperature [28]. Data
acquisition was carried out at FACS Calibur and analyzed using
CELLQUEST software.
Sb(III) and Sb(V) sensitivity profile of transfectants
Sb(III) and Sb(V) sensitivity profile of Transfectants growing at
0 mg, 20 mg, 50 mg were determined in the same procedure as it
was done for clinical isolates.
Sensitivity profile of transfectants towards other
antileishmanial drugs
Transfectants (promastigotes) growing at 50 mg of G418 were
assessed for their sensitivity towards miltefosine (SynphaBase),
paramomycin (Sigma) and amphotericin B (Sigma) through flow-
cytometry as described earlier [29].
Ethics statement. The clinical isolates were obtained from
the splenic biopsies carried out on the Leishmania patients. The
study was approved by the ethics committee of the Kala-azar
Medical Research Centre, Muzaffarpur and CDRI. The patients
provided a written consent and were informed before enrolment
to this study. Experiments on the animals (hamsters) were
performed following the approval of the protocol and the
guidelines of Institutional Animal Ethics Committee (IAEC) of
the CDRI which is adhered to National Guideline of CPCSEA
(Committee for the Purpose of Control and Supervision on
Experiments on Animals) under
the Ministry of Environment and Forest, Government of India.
The approval reference number 25/08/Para/IAEC dated 03.
08.2011.
Statistical analysis. The 50% inhibitory concentrations
(IC50s) of drugs were calculated by non linear regression obtained
through log [inhibitor] vs. response- variable slope of log dose/
response data on the drug [30]. The data were statistically
analyzed by the one way ANOVA test and a post Tukey test and
are presented as means and standard deviations (SDs) of three
determinations from at least three independent experiments. AP
value of ,0.05 was considered significant.
Accession numbers. Leishmania donovani 60S ribosomal pro-
tein L23a gene, complete cds has been submitted to NCBI and has
accession no GU121098.
Results
SAG sensitivity profile of clinical isolates in hamster and
macrophages
The in vitro and in vivo SAG sensitivity was assessed in clinical
isolates isolated from SAG responsive and unresponsive patients
from Muzaffarpur. The in vitro chemotherapeutic profile of
clinical isolates was summarized in (Table 1). The in vitro SAG
sensitivity assay was studied with both Sb (V) and Sb (III) and has
been found to be correlated to each other as confirmed by the
resistance index (Table 1). The chemotherapeutic sensitivity
profiles of clinical isolates tested in hamster model showed the
successful treatment of hamsters infected with S1 and S2 with
standard dose of SAG (80 mg/kg65 i.p.) with a percent
inhibition (PI) of 94.9762 for S1 and 96.91560.84 for S2.
SAG still exerted leishmanicidal action at 20 mg/kg65ip with PI
of 65.6763.75 for S1 and 70.64061.24 for S2. PI was
79.9862.41 for S1 and 84.8762.313 for S2 at 40 mg/kg65
i.p. whereas SAG failed to inhibit the multiplication of R1, R2
and R3 even at higher doses (Figure 1).
Molecular characterization of Ld60sRL23a. The
60sRL23a gene of L.donovani of 435 bp was successfully cloned
in T/A vector (Figure 2A, 2B) and sequenced which has 97%
identity to 60sRL23a of L.major, 95.86% to L.mexicana and 93.75%
L.infantum (Table 2). It was further sub-cloned in bacterial
expression vector pTriEx4 (Figure 2C), purified and eluted at
200 mM imidazole concentration. The size of the eluted
r60sRL23a was ,27 kDa (Figure 2D). Western blot analysis of
L.donovani promastigote lysate was performed with the polyclonal
anti-rLd60sRL23a antibody which detected protein in the whole
cell lysate of Ld belonging to the molecular wt of 16 kDa.
(Figure 2E). Immunolocalization studies further confirmed the
cytosolic existence of the protein (Figure 2F).
Comparative modeling technique was attempted for obtaining
three-dimensional coordinates of L.donovani 60S ribosomal protein
L23a. 60S ribosomal protein L25 of Saccharomyces cerevisiae S288c
(PDB id: 3U5E_chain X) was selected as template using hhpred
server on the basis of lower E-value, P-value and higher score.
This protein shows 43.80% similarity with L.donovani 60S
ribosomal protein L23a sequence (Figure 2 I). The best molecular
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model showed the DOPE score of 210568.408203. Ramachan-
dran plot obtained from Procheck shows high accuracy with 100%
residues within the allowed region (figure 2G, 2H). Figure 2(I)
shows the superimposed image of L.donovani 60sRL23a on
Saccharomyces cerevisiae L25.
Expression profile of 60sRL23a in different clinical isolates
of L.donovani
Since 60sRL23a was found to be over-expressed in the SAG
resistant strains as identified through differential proteomics
study it was further investigated for its expression profile in
several resistant and sensitive strains of L.donovani through real-
time PCR (Figure 3A). The study revealed the difference in the
expression levels of 60sRL23a between the sensitive and
resistant strains of L.donovani. There was ,two fold increase in
the expression of protein in resistant parasite (Figure 3B).
Expression profile of 60sRL23a in protein level was further
confirmed through western blot analysis with anti-r60sRL23a
antibody and was found to replicate the response of real-time
study as confirmed by the densitometric study through
chemidoc software (BIORAD) using Ld-actin as internal control
[31].
Overexpression of 60sRL23a in L.donovani S1 parasites
60sRL23a gene was further sub-cloned in Leishmania expression
vector pXG-’GFP+ (Figure 4A) and was transfected in S1 to check
whether this protein can alter the sensitivity profile of S1. The
western blot analysis of the whole cell lysate of S1
[60sRL23a+pXG-’GFP+] parasite with anti-60sRL23a antibody
revealed the identification of the protein at ,43 kDa and
,16 kDa mol wt. (Figure 4B), whereas with anti-GFP antibody
the protein bands were detected at ,43 kDa and ,27 kDa
(Figure 4C). The S1 lysate having vector alone [pXG-’GFP+]
exhibited a band at mol wt of 27 kDa when analyzed with GFP
antibody and at ,16 kDa when analyzed with r60sRL23a
antibody. This indicated towards the expression of GFP alone
(Figure 4C). The increased expression pattern of the protein in S1
[60sRL23a+pXG-’GFP+] parasite has been observed with in-
creased pressure of G418 at 0 mg/mL, 20 mg/mL and 50 mg/mL.
(Figure 4D).
Growth profile of transfectants S1 [60sRL23a+pXG-
’GFP+] and cell cycle analysis. Growth curve of transfectants
revealed proliferation in S1 [60sRL23a+pXG-’GFP+] as com-
pared to the transfectants having vector alone as well as WT (S1).
60sRL23a over expression was more when grown in presence of
50 mg/mL G418. The proliferation potential of S1
[60sRL23a+pXG-’GFP+] increases with the G418 concentration.
The proliferative potential of transfectants was also replicated in
amastigote stage (Figure 4F). The S1 transfected with empty vector
has growth curve same as that of S1 (Figure 4E).
Since, the growth curve of both parasite stages exhibited higher
proliferation, we investigated whether 60sRL23a protein is
associated with accelerating cell cycle. Cell cycle analysis of
transfectants revealed that S1 [60sRL23a+pXG-’GFP+] parasites
showed an accumulation in ‘G2M’ phase as compared to S1
Table 1. In vitro sensitivity profile of clinical isolates to Sb(V) and Sb(III).
Mean Resistance index ± SD
Strains Collection Area Clinical Drug Response SbIII SbV
S2 Laboratory Strain Sensitive 1a 1b
S1 Muzaffarpur Sensitive 0.76760.150 0.91960.099
R1 Muzaffarpur Resistant 3.85460.162 2.25860.071
R2 Muzaffarpur Resistant 3.61760.064 2.65360.113
R3 Muzaffarpur Resistant 3.06060.099 1.99760.114
S, sensitive; R, resistant.
1a, IC50, 24.4663.875 mg/mL.
1b, IC50, 94.1262.099 mg/mL.
Sb(III) and Sb(V) resistance indices were calculated using the formula IC50 isolates/IC50 Dd8.
doi:10.1371/journal.pntd.0002527.t001
Figure 1. Efficacy of SAG (80, 40, 20 mg/kg) against L.donovani
clinical isolates in golden hamsters: Parasitic burden was
estimated by splenic biopsy on day +7 post treatment and
percentage inhibition of parasite multiplication was calculated
in comparison to parasitic burden of untreated animal. NI, no
inhibition.
doi:10.1371/journal.pntd.0002527.g001
Table 2. Percent identity of Ld60sRL23a with different sp. of
Leishmania and Homo sapiens.
Species Percent identity
L.major 97.86
L.mexicana 95.86
L.infantum 93.79
L.braziliensis 84.08
H.sapiens 46.94
doi:10.1371/journal.pntd.0002527.t002
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containing vector [pXG-’GFP+] alone when analyzed by
flowcytometry at 0 h, 3 h, 6 h and 12 h. The S1(60sRL23a+
pXG-’GFP+) has 9, 13, 18, 43% of parasites in ‘G2/M’ phase and
19, 20, 18, 23% of parasites in ‘S’ phase. Whereas S1(pXG-’GFP+)
has 6, 10, 11, 13% of parasites in ‘G2/M’ phase and 14, 17, 23,
23% parasites in ‘S’ phase (Figure 4G). The proportion of
S1(pXG-’GFP+) in G0/G1 phase was 1.14, 0.5, 0.31 and 0.02%
whereas 1.19, 1.62, 1.42 and 1.10% of S1(60s+pXG-’GFP) in G0/
G1 phase at different time interval.
In vitro SAG sensitivity of transfectants
In vitro SAG sensitivity of transfectants maintained at 0, 20,
50 mg of G418 were assessed with both Sb (V) in macrophage
amastigote model and with Sb (III) in promastigotes. The
sensitivity profile of the transfectants to Sb (V) and Sb (III) is
depicted in (Figure 5A and 5B). S1 containing episomal over
expressed 60sRL23a growing at 50 mg/mL of G418 has IC50 i.e.
158.06664.28 for Sb(V) than of S1 expressing vector alone i.e.
92.50665.7. S1 [60sRL23a+pXG-’GFP+] growing at 20 mg/mL
of G418 also exhibited higher IC50 (123.265.117) as compared to
S1 (78.5566.5) containing vector alone. Whereas S1
[60sRL23a+pXG-’GFP+] growing at 0 mg/mL demonstrated the
IC50 comparable to S1[pXG-’GFP+] and S1. The sensitivity of
transfectants to Sb (III) and Sb (V) patterns were similar to each
other. The Sb (III) IC50 of S1 [60sRL23a+pXG-’GFP+] i.e.
61.5867.23 was found to be greater than S1 [pXG-’GFP+] i.e.
17.6761.71 at 50 mg/mL of G418, whereas at 20 mg/mL of G418
it was 47.3462.54 and S1 having empty vector has similar IC50 at
all concentrations of G418. In absence of G418 the IC50 of
transfectants were comparable.
Sensitivity profile of transfectants to other
antileishmanials (in vitro)
The transfectants were further checked for their sensitivity
towards other antileishmanial compounds (miltefosine, para-
momycin and amphotericin B) (Figure 6). S1 [60sRL23a+
Figure 2. Molecular characterization of L. donovani 60s Ribosomal L23a (60sRL23a). (A) PCR amplification of Ld60sRL23a. M: 1 kb
molecular mass marker; Lane 1&2: PCR amplificon of 60sRL23a; 3: negative control. (B) Clone confirmation of Ld60sRL23a in TA vector. M: 1 kb
molecular mass marker; Lane1: KpnI and HindIII digested TA-Ld60sRL23a; Lane2: Undigested TA-Ld60sRL23a. (C) Clone confirmation of Ld60sRL23a in
pTriEx-4 vector. M: 1 kb molecular mass marker; Lane1: KpnI and HindIII digested pTriEx-4 -Ld60sRL23a; Lane2: Undigested pTriEx-4-Ld60sRL23a. (D)
Expression (in E.coli), purification and elution of r60sRL23a at 200 mM of imidazole concentration of 60sRL23a and separation in 12%SDS
PAGE. M: Molecular wt. Markers, Lane 1 Whole cell lysate (WCL) of uninduced E.coli and Lane2: WCL of E.coli induced at 37uC and 1 mM IPTG; Lane3:
wash fraction; Lane 4, 5,6and7: purified protein (E) western blot analysis using anti r60sRL23a antibody. M: Molecular mass marker; Lane1:
WCL before IPTG induction; Lane2, WCL after IPTG (1 mM) induction at 37uC; Lane3: Purified protein; Lane 4: WCL of Ld. (F) Immunolocalization of
60sRL23a in Ld. F1: image of permeablized Ld with anti r60sRL23a and then FITC conjugated secondary antibody, F2: Image of non permeablized
Ld with anti r60sRL23a and then FITC conjugated secondary antibody, F3: negative control. (G) and (H) Superimposition of homology model (in
cyan color) on template (in green color) with RMSD of 0.667 A˚. (I) Alignment between L. donovani 60S ribosomal protein L23a of Ld and 60S
ribosomal protein L25 of Saccharomyces cerevisiae.
doi:10.1371/journal.pntd.0002527.g002
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pXG-’GFP+] showed ,7 fold decreased sensitivity towards
miltefosine (67.3869.64 mg/ml) and ,2.4 fold towards para-
momycin (142.1668.76 mg/ml). S1 [pXG-’GFP+] demonstrat-
ed IC50 of 8.661.44 for miltefosine and 57.11611.58 for
paramomycin. Whereas the transfectant showed comparable
IC50 for amphotericin B (0.20160.003 mg/ml for S1 [pXG-
’GFP+] and 0.174860.093 mg/ml for S1 [60sRL23a+pXG-
’GFP+]).
Discussion
The emergence of SAG resistance and the limited knowledge of
the mechanism by which parasite acquire resistance are the major
obstacle for the control of VL. Several SAG resistance studies were
done on the basis of differential proteomics or/and transcriptomics
and microarray to understand the parasite strategy to escape the
drug pressure. These studies led to the identification of several
Figure 3. Differential expression of 60sRL23a in clinical isolates by real time PCR. (A1) Relative expression of 60sRL23a in different
isolates to that of S1 as detected by real time PCR. The data are the mean of 6 SD of three independent fold expression estimated through three
independent RNA preparations. (Asterisks denotes highly significant differences from S1) (A2) Relative fold expression of Ld-actin (internal
control) in several clinical isolates. (B1) Differential pattern of expression of 60sRL23a in different isolates as analyzed by Western blot. (B2)
Fold expression of 60sRL23a in several clinical isolates as demonstrated through densitometric values (C) Ld-actin is used as internal control.
(the experiment was repeated three times with three independent whole cell lysate preparations of promastigotes along with their respective
loading control).
doi:10.1371/journal.pntd.0002527.g003
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Figure 4. Over expression of 60sRL23a in S1. (A) Clone confirmation of Ld60sRL23a in pXG-’GFP+ vector. M: 1 kb molecular mass marker;
Lane1: BamHI and EcoRV digested pXG-’GFP+Ld60sRL23a+; Lane2: Undigested pXG-’GFP+Ld60sRL23a+; (B) Western blot analysis using anti
r60sRL23a antibody. M: Molecular mass marker; Lane1: WCL of S1(WT); Lane 2: WCL of S1(pXG-’GFP+); Lane 3: WCL of S1(pXG-’GFP+Ld60sRL23a+);
(C) Western blot analysis using anti GFP antibody. M: Molecular mass marker; Lane1: WCL of S1(WT); Lane 2: WCL of S1(pXG-’GFP+); Lane 3:
WCL of S1(pXG-’GFP+Ld60sRL23a); (D) Western blot analysis of transfectants (D1) at different concentration of G418 using anti r60sRL23a
antibody (D2) at different concentration of G418 using anti Ld-actin antibody. (E) Growth curve of transfectants (Promastigote) (F) Growth
curve of transfectants (amastigote) (G) Cell cycle analysis of Transfectants.
doi:10.1371/journal.pntd.0002527.g004
Figure 5. SAG sensitivity profile of transfectants. (A) with Sb(V); (B) with Sb(III) (The results are the mean 6SD of three independent IC50
estimation experiment of each group.)
doi:10.1371/journal.pntd.0002527.g005
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proteins, playing crucial role in liberating the drug pressure,
including ribosomal proteins [6–8]. . The enhanced expression of
ribosomal proteins has been reported in tumors such as breast
cancers, prostate cancers and hepatocellular cancers [32]. These
ribosomal proteins have not been studied in detail in relation to
SAG resistance in Leishmania. In this study, therefore, we have
evaluated the involvement of 60sRL23a in SAG resistance using
five clinical isolates which were isolated from kala-azar patients
(Muzaffarpur) and their SAG sensitivity was further verified in vitro
(macrophage and amastigote model) and in vivo (hamster model).
SAG sensitivity profile of sensitive and resistant isolates in vitro and
in vivo was comparable. S2 (Dd8), a WHO reference laboratory
strain of L.donovani was used in this study to assess the resistance
index of isolates. Resistance index of different resistant clinical
isolates (R1, R2, R3) revealed that their response to Sb (V) and Sb
(III) were similar. In vivo response of the resistant isolates to SAG in
hamster model exhibited no inhibition even at higher concentra-
tion of SAG where as the S1, S2 exhibited 94.9762.0% and
96.91560.84% inhibition. The sensitive isolates responded even at
the lower doses of SAG (20 and 40 mg/kg65i.p.). In vitro and in
vivo SAG sensitivity profile of all the isolates replicated the patients’
response and confirmed the persistence of SAG response of clinical
isolates even after several passages in hamster. In order to assess
the association of 60sRL23a in SAG resistance we cloned,
expressed and purified the protein which exhibited very close
homology with L.major 60sRL23a to the tune of 95% and 45%
identity with humans indicating towards the difference among the
humans and parasite’s entity. The protein’s mismatched homology
with humans can present the protein as a potential drug target.
Immunoblot study of L.donovani promastigote lysate with the
polyclonal anti-rLd60sRL23a antibody has revealed one dominant
protein of 16 kDa mol wt. This protein was identified earlier at
lower molecular weight range in proteomic studies which is
approximately identical to its observed molecular mass [10]. The
protein has been observed to have a cytosolic localization in the
parasite, though earlier in the proteomic study it was identified in
the membrane fraction. The protein is a well known member of
large subunit of ribosomes so it is obvious for its attachment to
endoplasmic reticulum thus it would have eventually been
identified in the membrane fraction in the proteomic study. To
study the expression level of 60sRL23a in different clinical isolates
real time and immunoblot analysis was done and it revealed the 2
fold expression of the transcript and protein in the resistant strain
as compared to the sensitive one, verifying the differential
proteomics finding [10]. Differential regulation of ribosomal
proteins has been utilized by cells to cater their needs such as
replication, transcription, delaying apoptosis and proliferation,
thus helping the cell to escape the stress conditions [33]. In this
study whether 60sRL23a could modulate the SAG sensitivity
profile of parasite, protein has been over expressed in S1 in pXG-
’GFP+ vector having GFP tag in C-terminus end of the protein.
Immunoblot analysis with 60sRL23a polyclonal antibody revealed
the ,43 kDa protein in the lysate of S1 transfected with
60sRL23a gene containing vector, verifying over expression of
GFP tagged 60sRL23a. The immunoblot analysis with the GFP
antibody identified two protein bands at ,43 kDa and ,27 kDa,
indicating the detachment of GFP protein from combined entity of
60sRL23a+pXG-’GFP+ after expression (Figure 4C). This ensures
the expression of protein returns in its original length after fusion
protein expression. Transfectants expression profile in increasing
G418 concentration indicated the increased protein expression
pattern with increasing amount of G418 (Figure 4D) i.e. , two
fold expression of GFP tagged 60sRL23a in parasites growing in
50 mg/mL G418 as compared to parasites residing with 20 mg/mL
G418, whereas no expression of GFP tagged 60sRL23a has been
seen in 0 mg/mL of G418. Transfectants growth profile was
analyzed by counting parasites per day for each transfectants and a
clear proliferation has been observed in 60sRL23a over expressing
parasites. The transfectants S1(60sRL23a+pXG-’GFP+) growing
at 50 mg/mL of G418 has more proliferative potential as
compared to transfectants growing at 0 mg/mL and 20 mg/mL
of G418, indicating the increasing expression of protein leading
the parasite proliferation. As the growth curve results exhibited
greater number of parasites in transfectants over expressing
60sRL23a, thus the cell cycle progression of a synchronized
transfected and control parasite population was analyzed to
identify its relation with 60sRL23a expression. Parasites exhibited
the tendency towards ‘G2/M’ phase as increasing number of
parasites are seen in this phase wherein parasite progresses at
different time intervals in compared to the control S1
Figure 6. Sensitivity profile of transfectants with other antileishmanial drugs. (A) Amphotericin B, (B) Miltefosine and Paramomycin ( The
results are the 6SD of three independent IC50 estimation experiment of each group.)
doi:10.1371/journal.pntd.0002527.g006
Role of 60s Ribosomal L23a in SAG Resistance
PLOS Neglected Tropical Diseases | www.plosntds.org 9 December 2013 | Volume 7 | Issue 12 | e2527
(pXG-’GFP+) one. The different proportion of both parasites
[S1(pXG-’GFP+) and S1(60s+pXG-’GFP+)] in S phase were
approximately same at different time interval. In G0/G1 phase
number of parasites were decreased in S1 (60s+pXG-’GFP+) as
compared to S1(pXG-’GFP+) revealing no arrest and a smooth
progression to G2M phase. Whereas in G2M phase at 8 hrs and
12 hrs the S1(60s+pXG-’GFP+) progressively increased in com-
parison to S1(pXG-’GFP+) leading to rapid proliferation of
parasites. Cell cycle progression pattern of transfectants recon-
firmed the proliferation of S1(60sRL23a+pXG-’GFP+). Cellular
proliferation as one of the extra ribosomal functions of ribosomal
proteins have been reported to alter the cell cycle by interacting
with cyclin-dependent kinases (Cdk) and regulatory molecules of
cell cycle check points [34,35]. Although Cdk are absent in
Leishmania still apoptosis like cell death has been evidenced in
Leishmania [36–38]. Transfectants were checked for their SAG
sensitivity in vitro in macrophage-amastigote model Sb (V) as well
as in the promastigotes for Sb (III) directly. Results revealed the in
vitro SAG sensitivity of transfectants maintained at 0, 20, 50 mg of
G418 were assessed with both SbV in macrophage amastigote
model and with Sb (III) in promastigotes. The sensitivity profile of
the transfectants to Sb (V) and Sb (III) is depicted in (Figure 5A,
5B). S1 containing episomally over-expressed 60sRL23a growing
at 50 mg/mL showed 1.7 fold higher IC50 (158.06664.28) for Sb
(V) than IC50 (92.50665.7) of S1 expressing vector alone.
S1(pXG-’GFP+60sRL23a) growing at 20 mg/mL of G418 also
exhibited higher IC50 (123.265.117) which is 1.5 fold as compared
to S1(78.5566.5). Whereas S1 (pXG-’GFP+60sRL23a) growing at
0 mg/mL of G418 demonstrated the IC50 comparable to S1
(pXG-’GFP+) and S1. The sensitivity of transfectants to Sb (III)
and Sb (V) patterns were similar to each other. The Sb (III) IC50
(61.5867.23) of S1 (pXG-’GFP+60sRL23a) was 3.5 fold higher
than S1 (pXG-’GFP+) (17.6761.71) at 50 mg/mL of G418,
whereas at 20 mg/mL of G418 it was 2.7 fold higher. In absence of
G418 the IC50 of transfectants were comparable. The IC50 of
S1(pXG-’GFP+60sRL23a) growing at 50 mg/mL was 1.2 fold
higher than the IC50 of transfectants growing at 20 mg/mL. This
sensitivity profile of transfectants to Sb (V)/Sb (III)and increasing
expression pattern of 60sRL23a in response to varying G418
concentration revealed the SAG sensitivity profile and 60sRL23a
expression pattern is inversely correlated. The IC50 values of
transfectants, were ,1.3 to 1.8 fold higher for Sb (V) and ,1.2 to
1.4 fold higher for Sb (III) to all the three resistant isolates,
depicting the comparable resistance acquired by the transfectants
to that of resistant isolates. Since SAG helps in sustaining innate as
well as adaptive immunity against Leishmania by generating ROS
and NO, higher proliferating capacity would increase the chances
of the parasite to survive the intracellular host killing mechanism
and combating the drug pressure [39]. Cellular proliferative
potential of 60sRL23a and decreased SAG sensitivity of
transfectants further emphasized the need to check its sensitivity
profile for other antileishmanial drugs such as miltefosine,
paramomycin and amphotericin B (Figure 6). Results revealed
the decreased sensitivity of transfectants towards miltefosine and
paramomycin. Whereas transfectants retained unaltered sensitivity
towards amphotericin B. Paramomycin in general is known to
inhibit protein synthesis by targeting ribosomal proteins and
resistant strains of paramomycin revealed upregulated translation-
al/ribosomal proteins to combat the drug pressure [8]. On the
other hand the resistance mechanism of miltefosine involves
several defect in inward translocation and increased efflux of drugs
[40]. Since paramomycin is known to inhibit protein synthesis and
the exact working mechanism of miltefosine and SAG is still
unknown, the pathways of these drugs may do the cross talk
somewhere or the toxicity of these drugs could have been
overtaken by the parasite through increased cellular proliferation.
In the light of above observation increased proliferative potential
may strengthen the parasite to redistribute or lower the drug
pressure hence providing a prospect to escape the drug pressure.
Amphotericin B being the most successful drug among these and
no resistance cases reported till date, further revealed its unique
mechanism unbeatable by the parasite. Despite of its peerless
therapeutic results, its toxicity and cost factors further compelled
us to rejuvenate the safe traditional drugs. Down regulation of
60sRL23a could validate the finding of the present study but as
RNAi machinery is absent in L.donovani and only knockout remains
the only way to study the down regulation effect of the gene, but
knockout 60sRL23a would be futile due to multicopy of the gene
present in the genome of Leishmania. Presence of multicopy of
60sRL23a again indicates the protein to be an essential
component of parasite that could be used by the parasite in
different ways as and when so ever needed. Hence this study could
only confirm the after effects of up regulation of 60sRL23a. Study
further revealed that parasite could use its usual protein to perform
an unusual function such as cellular proliferation to combat
pressure of different drugs carrying out different anti-parasitic
pathway. Indian subcontinent is now relying on several other drug
combinations other than SAG, but parasites had developed
resistance against these drug combinations under laboratory
conditions [41]. To win the battle against Leishmaniasis searching
new drugs or combinations against Leishmania is not sufficient but
our understanding for the resistance mechanism has to be
explored enough to strengthen the new chemotherapeutic strategy.
SAG has not been in use for some time on the Indian
subcontinent, and although the removal of drug pressure is
expected to allow the return of the sensitive parasites by natural
selection, although this is not universally accepted [42,43,4,5]. Our
understanding regarding resistance mechanism is in its infancy,
this study will help to focus on the substantial role played by the
ribosomal proteins in disease progression by assisting the parasite
to escape the drug pressure.
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